PET Imaging

Positron emission tomography (PET) is a nuclear imaging technology (also referred to as molecular imaging) that enables visualization of metabolic processes in the body. The basics of PET imaging is that the technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide (also called radiopharmaceuticals, radionuclides or radiotracer). The tracer is injected into a vein on a biologically active molecule, usually a sugar that is used for cellular energy. PET systems have sensitive detector panels to capture gamma ray emissions from inside the body and use software to plot to triangulate the source of the emissions, creating 3-D computed tomography images of the tracer concentrations within the body.

18F-rhPSMA-7.3 PET image showing multiple areas of uptake in the prostate gland in a man with newly diagnosed prostate cancer Photo courtesy of Blue Earth Diagnostics
News | Prostate Cancer
Blue Earth Diagnostics Announces Efficacy and Safety Results from Phase 3 LIGHTHOUSE Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Newly Diagnosed Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
arrow
A team led by UTHealth Houston's K. Lance Gould, MD, (center) used PET imaging technology (shown above) to map coronary blood flow and its outcomes among heart disease patients. (Photo by UTHealth Houston)
News | PET Imaging
PET Technology More Effective Than Angiogram at Determining Need for Coronary Stents, Bypass Surgery

December 1, 2022 — A new method for determining whether patients with heart disease need coronary stents or bypass ...

Time December 01, 2022
arrow
18F-rhPSMA-7.3 PET image showing prostate cancer spread beyond the prostate region (Photo courtesy of Blue Earth Diagnostics)
News | PET Imaging
Blue Earth Diagnostics Announces Results on Clinical Factors Impacting Detection Rates from Phase 3 SPOTLIGHT Trial of Investigational PET Imaging Agent 18F-rhPSMA-7.3 in Biochemical Recurrence of Prostate Cancer

November 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time November 02, 2022
arrow
Top trends boosting the industry expansion through 2028
Feature | Contrast Media | By Shankar Khatkale
Imaging Contrast Agents Global Market Outlook

According to a recent study from market research firm Graphical Research, the global imaging agents market size is set ...

Time November 02, 2022
arrow
UVA embedded links to their images and interactive radiology reports into Epic MyChart, allowing patients to review and share their Interactive Multimedia Reports and associated findings marked on live images through the hospital's patient portal.
Sponsored Content | Case Study | Enterprise Imaging
Improving Radiology Reporting and Workflow With Interactive Multimedia

Reporting produces the tangible work product of diagnostic radiologists. Reports should reflect the expertise of the ...

Time October 30, 2022
arrow
The oral presentation includes additional results from Blue Earth's Phase 3 SPOTLIGHT study evaluating the impact of clinical factors on the detection rate of 18F-rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence based on elevated PSA following prior therapy
News | PET Imaging
Blue Earth Diagnostics Highlights Presentations on Axumin (Fluciclovine F 18) and Investigational 18F-rhPSMA-7.3 in Biochemically Recurrent Prostate Cancer

October 25, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 25, 2022
arrow
Company announces SCINTIX as new product name for its flagship biology-guided radiotherapy technology
News | PET-CT
RefleXion Highlights New Cancer Treatment Research Abstracts for Presentation at ASTRO 2022

October 24, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 24, 2022
arrow
18F-SMBT-1 PET studies showed that beta-amyloid+ Alzheimer’s disease (AD) patients, but most importantly, beta-amyloid+ controls (CN) have significantly higher regional 18F-SMBT-1 binding than beta-amyloid- CN, with 18F-SMBT-1 retention highly associated with beta-amyloid burden. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of beta-amyloid accumulation.
News | PET Imaging
Novel PET Imaging Agent Detects Earliest Signs of Alzheimer's Disease

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18F-rhPSMA-7.3 clinical data and images.
News | PET Imaging
Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3

October 19, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time October 19, 2022
arrow
The Omni PET/CT platform accommodates patients across more care areas and offers a scalable design to easily enable future-ready capabilities and multi-dimensional scalability
News | PET-CT
GE Healthcare Introduces Omni Legend: A First-of-its-Kind All-Digital PET/CT System to Drive Efficiency, Enhance Diagnostics, and Deliver on Precision Medicine

October 17, 2022 — At the European Association of Nuclear Medicine (EANM) Annual Meeting, GE Healthcare proudly ...

Time October 17, 2022
arrow
News | PET Imaging
Blue Earth Diagnostics Announces FDA Acceptance of New Drug Application for 18F-rhPSMA-7.3, a Radiohybrid Prostate-Specific Membrane Antigen-Targeted PET Imaging Agent for Prostate Cancer

September 28, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time September 28, 2022
arrow
Ground-breaking research funded by National Cancer Institute
News | PET-CT
Xoran Partners With WVU to Develop PET/CT Scanner for Head and Neck Cancers (HNCs)

September 28, 2022 — Xoran Technologies is engaged in a ground-breaking research project to develop a PET/CT scanner for ...

Time September 28, 2022
arrow
For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative imaging and service solutions to healthcare facilities regardless of their size, location or capital budget. That vision is as strong today as it was back in 1980.
News | PET-CT
SMS first to bring Mobile Digital PET/CT to North Dakota and Montana

September 13, 2022 — For over 40 years the vision of Shared Medical Services (SMS) has been to provide innovative ...

Time September 13, 2022
arrow
Patients with detectable PSA (0.2-2.0 ng/mL) post-prostatectomy considered for salvage radiotherapy undergoing 18F-DCFPyl PSMA PET/CT staging. Image created by M.Ng et al, GenesisCare, Melbourne, Australia.
News | Prostate Cancer
New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50% of Prostate Cancer Patients

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
Societies Outline Recommendations for Hardware and Software, Training, Competency, Cross-specialty Collaboration, More
News | SPECT-CT
New ASNC-led Guideline Details How to Use CT in Hybrid Nuclear-CT Cardiac Imaging

September 7, 2022 — The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to ...

Time September 07, 2022
arrow
Three machine deal expands potential of biology-guided radiotherapy to Pacific Northwest
News | PET Imaging
RefleXion Announces Multi System Contract with Select Healthcare

August 30, 2022 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT), a ...

Time August 30, 2022
arrow
NorthStar will provide Clovis with its environmentally preferred, high purity non-carrier-added (n.c.a.) Ac-225
News | PET Imaging
Independent Clinical Studies Published Regarding Performance of Axumin (Fluciclovine F 18) PET Imaging in Patients with Recurrent Prostate Cancer Undergoing Androgen Deprivation Therapy (ADT)

July 20, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time July 20, 2022
arrow
Radialis Inc. today announced that it has received clearance to market the Radialis PET Imager, an organ-targeted positron emission tomography (PET) system, in the United States
News | PET Imaging
Radialis PET Imaging Receives FDA Clearance

July 19, 2022 — Radialis Inc. today announced that it has received clearance to market the Radialis PET Imager, an organ ...

Time July 19, 2022
arrow
The global molecular imaging market is estimated to be USD 6,750.1 million in 2021 and is expected to witness a CAGR of 7.84% during the forecast period
News | Molecular Imaging
Global Molecular Imaging Market Report

July 11, 2022 — The "Molecular Imaging Market, by Application (Cancer, Heart Disease, Brain Disorder), by Technology ...

Time July 12, 2022
arrow
News | PET-CT
Aetna Reverses Cardiac PET/CT Non-coverage Policy

July 11, 2022 – The American Society of Nuclear Cardiology (ASNC) and the Society of Nuclear Medicine and Molecular ...

Time July 11, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now